How GLP-1 drugs are changing drug plan strategy for employers

Few drug categories have forced employers to rethink benefits strategy as quickly as GLP-1 medications.

For many plan sponsors, the initial challenge started when the drug was approved by Health Canada for diabetes but was being prescribed off-label for weight management. This led to a spike in prescribing that was not necessarily for the approved indication. This led to plan sponsors and insurers scrambling to ensure that GLP-1 claims were actually for diabetes, or that there were appropriate controls in plan design. Then the conversation widened when Wegovy got approved for weight management. Now employers are hearing about potential applications connected to chronic disease, inflammation, cardiovascular health, kidney health, addiction support, and other areas of medicine.

The message for plan sponsors is that GLP-1s may not be a passing trend. They are part of a much larger shift in how chronic disease may be treated, managed, and funded through employer-sponsored drug plans.

That creates a difficult but important question.

What do you want your drug plan to do?

For years, many employers could manage drug plans with familiar tools. Generic substitution. Prior authorization. Maximums. Managed formularies. Pooling. Renewal reviews. Those tools still matter but GLP-1s create a more strategic challenge because they sit at the intersection of cost, employee health, chronic disease management, productivity, disability risk, and plan sustainability.

Even considering the recent approval of generic GLP-1s in Canada, they are expensive. They are in demand. They may be clinically meaningful for some employees. They may also require behavioural and lifestyle support to be effective over time.

A plan sponsor has several choices to make.

First, should the plan cover GLP-1s only for diabetes, or also for weight management where approved? Some plans still treat weight management drugs as lifestyle medications. That view is becoming harder to defend as obesity is increasingly understood as a complex disease state with links to other health risks.

Second, if coverage is expanded, what controls should be in place? Employers may consider prior authorization, clinical criteria, step therapy, annual maximums, or managed access. The goal should be to make sure the plan supports appropriate use.

Third, what wraparound support is needed to help patients be successful? GLP-1s can come with side effects. Some people discontinue treatment. Others may stop once they reach a weight goal. For employees using these medications for weight management or chronic disease support, the drug may be only one part of the equation. Nutrition support, coaching, mental health resources, and chronic disease education may help improve outcomes.

This is where plan strategy becomes more sophisticated.

An employer could simply say yes or no to coverage. But a better conversation asks how access, cost control, and health outcomes fit together. For example, a plan sponsor may choose to cover weight management medications up to a defined annual maximum while monitoring utilization. That approach gives employees access, creates a budget boundary, and allows the employer to review experience before making broader commitments.

Another employer may decide to cover GLP-1s for specific clinical indications only, while investing in wellness, diabetes management, and prevention programs.

A third may take a more comprehensive chronic disease strategy approach, connecting drug coverage with education, preferred pharmacy arrangements, digital health tools, and employee communication.

The right answer depends on the workforce, the budget, the benefits philosophy, and the employer’s tolerance for risk.

What is not ideal is no strategy or plan.

If plan sponsors do not make intentional decisions about GLP-1s, the plan experience will eventually make decisions for them. Costs may rise before leadership has agreed on a position. Employees may receive inconsistent messages. HR may be left trying to explain coverage rules that were never clearly connected to a broader plan strategy.

There is also a larger point. Drug plan management is no longer only about reducing costs. It is about deciding where investment in health may produce longer-term value. In chronic disease management, early and effective treatment can affect more than a drug budget. It may influence absence, disability duration, productivity, engagement, and the employee’s ability to stay well and working. Those outcomes are harder to measure than a monthly claim report, but they matter.

That does not mean every employer should open coverage without limits. Sustainability is still critical. A plan that cannot be maintained is not serving anyone well. But it does mean employers should look at GLP-1s through a strategic lens rather than a reactive one.

A practical starting point is to review the current drug plan. What is covered today? What is excluded? How are diabetes, weight management, and chronic disease medications treated? What prior authorization rules apply? What controls are in place to decide when a new drug is eligible for coverage? What does the claims data show? What employee communication will be needed if changes are made?

Then connect those answers to the larger benefits philosophy. Do you want your plan to focus on serious health conditions? Everyday affordability? Prevention? Talent competitiveness? Family support? Long-term health outcomes?

GLP-1s make these questions harder to avoid. They also create an opportunity. Employers who act thoughtfully can build a drug plan strategy that is clear, defensible, compassionate, and sustainable.

Need help reviewing your drug plan strategy in light of GLP-1s and other emerging treatment trends? Contact Contact us to start a conversation about building a sustainable plan that supports employee health while managing cost and risk.